Why Pacira BioSciences is on investors’ radar today

Pacira BioSciences (PCRX) has been drawing attention after a mixed share price pattern, with a 6.7% gain over the past month contrasting with negative returns over the past 3 months and year to date.

At the current share price of $21.91, Pacira BioSciences shows a mixed picture, with a 6.7% 30 day share price return set against a 10.4% year to date share price decline and a 68.3% five year total shareholder return decline. This suggests that recent momentum is tentative rather than firmly established.

If Pacira’s recent swings have you thinking about where else growth stories might appear, it could be a good time to scan our list of 27 healthcare AI stocks as potential next ideas.

With Pacira shares at $21.91 and trading at a reported discount to analyst targets and intrinsic estimates, the key question is whether this reflects an undervalued pain management specialist, or whether the market already prices in future growth potential.

Most Popular Narrative: 24.4% Undervalued

With Pacira BioSciences last closing at $21.91 against a most-followed fair value narrative of $29, the gap between market price and projected value is hard to ignore.

The new strategic partnership with Johnson & Johnson MedTech for ZILRETTA is expected to double sales coverage and significantly expand reach across new physician specialties and healthcare systems, providing a forward catalyst for revenue growth in 2026 and beyond.

Want to see what sits behind that optimism on revenue and margins, plus the profit multiple used to reach $29 per share? The narrative leans on accelerating earnings, tempered revenue growth, and a specific discount rate that pulls those future numbers back to today. Curious which assumptions really carry the valuation and how sensitive it is to them? The full narrative lays out the playbook.

Result: Fair Value of $29 (UNDERVALUED)

However, this hinges on broader uptake of EXPAREL and ZILRETTA, and any pricing pressure or slower product adoption could quickly challenge that 24.4% undervalued story.

Another View: Rich Earnings Multiple Raises Questions

That 24.4% undervalued story sits awkwardly beside Pacira’s current P/E of 126.1x, compared with an industry average of 20x, a peer average of 18x, and a fair ratio of 17.8x that the market could move toward. If sentiment cools, does this high bar leave much room for error?

Next Steps

With the mixed messages on valuation and earnings multiples, it helps to look at the underlying data yourself and act while it is still fresh. To see what investors are currently optimistic about, take a closer look at the company’s 3 key rewards.

Looking for more investment ideas?

If Pacira has sharpened your thinking, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities that fit your style before others do.

• Target long term compounding by scanning our list of 46 high quality undervalued stocks that pair sensible prices with quality fundamentals.
• Prioritise resilience by checking out 74 resilient stocks with low risk scores, focused on companies with lower risk profiles that may suit a steadier approach.
• Hunt for early stage potential with the 30 elite penny stocks with strong financials that pass fundamental filters instead of relying on hype.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.